However, previous experimental and clinical studies provide evidence that XOR inhibitors have the potential to prevent the development of NAFLD, through attenuation of hepatic lipid accumulation, insulin resistance, and activation of macrophage and NLRP3 inflammasome [34,35,36]. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.